Pramipexole is a dopamine agonist used in the treatment of Parkinson’s disease and Restless legs syndrome. Although off-label, the use of Pramipexole as an adjunct therapy in treatment resistant depression has recent...Pramipexole is a dopamine agonist used in the treatment of Parkinson’s disease and Restless legs syndrome. Although off-label, the use of Pramipexole as an adjunct therapy in treatment resistant depression has recently been documented in the literature with promising results. We present a 75-year-old male with MDD who has failed trials of SSRIs, SNRIs, TCAs, SGA, TMS, Ketamine, and ECT who was initiated on Pramipexole. We discuss, based on existing literature, the probability of a favorable long-term response to Pramipexole and the potential side effects for our patient. We also highlight the need for future studies designed to test the efficacy of Pramipexole in geriatric patients with TRD.展开更多
Background The majority of coronavirus disease 2019(COVID-19)symptom presentations in adults and children appear to run their course within a couple of weeks.However,a subgroup of adults has started to emerge with eff...Background The majority of coronavirus disease 2019(COVID-19)symptom presentations in adults and children appear to run their course within a couple of weeks.However,a subgroup of adults has started to emerge with effects lasting several months or more after initial infection,which raises questions about the long-term physical,mental and social health effects of COVID-19 in the pediatric population.The purpose of this review was to determine these impacts well into the second year of the pandemic.Methods A search was conducted using PubMed,Web of Science,Science Direct,and Cochrane between 11/1/2019 and 9/1/2021.Search inclusion criteria were as follows:(1)COVID-19 illness and symptoms in children;(2)severe acute respiratory syndrome coronavirus 2 in children;(3)English language;and(4)human studies only.Results The few studies that have documented long-term physical symptoms in children show that fatigue,difficulty in concentrating(brain fog),sleep disturbances,and sensory problems are the most reported outcomes.Most studies examining the impact of COVID-19 in pediatric populations have focused on initial clinical presentation,and symptoms,which are similar to those in adult populations.In addition,COVID-19 has had a moderate impact on children and adolescents’social environment,which may exacerbate current and future physiological,psychological,behavioral,and academic outcomes.Conclusions There are limited studies reporting long physical symptoms of COVID-19 in the pediatric population.However,pediatric COVID-19 cases are underreported due to low rates of testing and symptomatic infection,which calls for more longitudinal studies.Children who have experienced COVID-19 illness should be monitored for long physiological,psychological,behavioral,and academic outcomes.展开更多
文摘Pramipexole is a dopamine agonist used in the treatment of Parkinson’s disease and Restless legs syndrome. Although off-label, the use of Pramipexole as an adjunct therapy in treatment resistant depression has recently been documented in the literature with promising results. We present a 75-year-old male with MDD who has failed trials of SSRIs, SNRIs, TCAs, SGA, TMS, Ketamine, and ECT who was initiated on Pramipexole. We discuss, based on existing literature, the probability of a favorable long-term response to Pramipexole and the potential side effects for our patient. We also highlight the need for future studies designed to test the efficacy of Pramipexole in geriatric patients with TRD.
文摘Background The majority of coronavirus disease 2019(COVID-19)symptom presentations in adults and children appear to run their course within a couple of weeks.However,a subgroup of adults has started to emerge with effects lasting several months or more after initial infection,which raises questions about the long-term physical,mental and social health effects of COVID-19 in the pediatric population.The purpose of this review was to determine these impacts well into the second year of the pandemic.Methods A search was conducted using PubMed,Web of Science,Science Direct,and Cochrane between 11/1/2019 and 9/1/2021.Search inclusion criteria were as follows:(1)COVID-19 illness and symptoms in children;(2)severe acute respiratory syndrome coronavirus 2 in children;(3)English language;and(4)human studies only.Results The few studies that have documented long-term physical symptoms in children show that fatigue,difficulty in concentrating(brain fog),sleep disturbances,and sensory problems are the most reported outcomes.Most studies examining the impact of COVID-19 in pediatric populations have focused on initial clinical presentation,and symptoms,which are similar to those in adult populations.In addition,COVID-19 has had a moderate impact on children and adolescents’social environment,which may exacerbate current and future physiological,psychological,behavioral,and academic outcomes.Conclusions There are limited studies reporting long physical symptoms of COVID-19 in the pediatric population.However,pediatric COVID-19 cases are underreported due to low rates of testing and symptomatic infection,which calls for more longitudinal studies.Children who have experienced COVID-19 illness should be monitored for long physiological,psychological,behavioral,and academic outcomes.
